Worried cancer patients are flooding charity with calls asking whether fat jabs are safe to use
The rise in queries prompted the charity's Dr Owen Carter to urge caution before using the jabs
FAT JAB QUERIES Worried cancer patients are flooding charity with calls asking whether fat jabs are safe to use
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
WORRIED cancer patients are flooding a charity with calls asking whether fat jabs are safe to use.
Some of the concerns are being raised by those already having treatment such as chemo or hormone therapy.
Sign up for Scottish Sun
newsletter
Sign up
But others are fretting that using weight loss medication could increase their cancer risk.
Other questions posed to Macmillan Cancer Support's helpline include asking if they were safe for someone who has had a previous thyroid cancer diagnosis, or before cancer surgery.
Studies suggest the jabs might reduce the risk of some cancers but research is ongoing and they may not be safe for everyone.
The rise in queries prompted the charity's Dr Owen Carter to urge caution before using the jabs.
He said: 'Recently we have seen a noticeable increase in calls to Macmillan's support line and a flurry of messages on our online community about weight loss drugs.
'It's understandable that lots of people are interested in new drugs which accelerate weight loss, particularly if they want to manage their weight before or after treatment for cancer.
'While 'quick fixes' may seem attractive, we simply do not know enough about the long-term impact of these weight loss medications to recommend them if they're not prescribed by a specialist.
'Additionally, certain weight loss medications carry warnings about a potential link with thyroid cancer.
'However, we know that eating well and staying as active as possible are proven to help people feel better, increase their energy levels and strengthen their immune systems, which can help them to manage their weight and cope better with cancer treatment.'
Eating well and staying active were better ways to increase energy levels and strengthen immune systems, which, in turn, would help manage weight and cope with treatment, he added.
Doc gives advice on how to tackle Mounjaro side effect of excess loose skin
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
41 minutes ago
- Scottish Sun
The strange sign in your EARWAX that can predict if you'll develop devastating brain disorder
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) YOUR earwax could be used to predict whether you'll develop Parkinson's, scientists say, About 153,000 people in the UK live with the devastating neurological disorder, caused by a loss of nerve cells in the brain. Sign up for Scottish Sun newsletter Sign up 2 Earwax could be used to predict whether someone will get Parkinson's or catch the disease in its early stages Credit: Getty The progressive disease is characterised by symptoms such as tremors, slow movement and muscle stiffness, which slowly get worse. According to researchers Zhejiang University in China, most Parkinson's treatments only slow the disease's progression, so early diagnosis is important for managing symptoms. But current tests for spotting the disease - such as brain scans or rating scales - can be expensive or subjective, they said. Now, a study published to Analytical Chemistry suggests that earwax could be used as a cost effective way to screen people for Parkinson's. Researchers claimed they'd developed a new AI system that could help catch the disease at an early stage, using earwax samples. Previous studies have shown that changes in sebum - an oily substance secreted by the skin - could help identify people with Parkinson's. Sebum from people with the disease may have a characteristic, musky smell because volatile organic compounds released by sebum are altered by disease progression. But sebum on the surface of the skin isn't a reliable substance for testing as it's exposed to pollution or humidity, which can change its composition. However, sebum in ear canals is sheltered from the elements. Seeing as the oily substance is the main component of earwax and it's easy to sample, researchers decided to use it for their screening tool. Good Morning Britain star reveals Parkinson's diagnosis after tragic death of his wife To identify the compounds released by sebum in people with Parkinson's, the researchers swabbed the ear canals of 209 participants, more than half of which were diagnosed with the condition. They then analysed wax samples, identifying four volatile organic compounds specific to people with Parkinson's. Those include ethylbenzene, 4-ethyltoluene, pentanal, and 2-pentadecyl-1,3-dioxolane. Researchers said these could serve as potential biomarkers for Parkinson's. Using these findings, they were able to develop a system that inexpensively screens for Parkinson's. Everything you need to know about Parkinson's Parkinson's is a progressive neurological condition, meaning that it causes problems in the brain and gets worse over time. It affects around 153,000 people in the UK. People with Parkinson's don't have enough of the chemical dopamine because some of the nerve cells that make it have stopped working. This can cause a range of more than 40 symptoms, but the three main ones are: Tremor (shaking) Slow movement Rigidity (muscle stiffness) Other common signs include: Mild memory and thinking problems Trouble sleeping Issues with balance Pain Anxiety and depression Shuffling walk with very small steps Difficulty making facial expressions Loss of sense of smell Problems peeing Constipation The four main ways of managing Parkinson's include medication, staying active, exploring occupational therapy, physical therapy and speech and language therapy, and monitoring symptoms. Source: Parkinson's UK and NHS They trained an artificial intelligence olfactory system - a robotic model that can mimic how we smell - with their ear wax compound data. They found it was able to categorise samples with and without Parkinson's with 94 percent accuracy. Researchers suggested their system could be used to a first-line screening tool for early Parkinson's detection and could help improve care for condition by making it possible to administer treatments earlier. Author Hao Dong said: 'This method is a small-scale single-center experiment in China." 2 'The next step is to conduct further research at different stages of the disease, in multiple research centres and among multiple ethnic groups, in order to determine whether this method has greater practical application value.' Earlier this year, scientists warned of a surge in cases of Parkinson's. They said 25 million people across the world will be living with the debilitating brain condition by 2050. Researchers from Capital Medical University in Beijing, China, estimated that an ageing population would drive the surge in cases of Parkinson's disease over the next 25 years. According to Parkinson's UK, the condition is the fastest growing neurological condition in the world.
Reuters
an hour ago
- Reuters
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
June 20 (Reuters) - Eli Lilly (LLY.N), opens new tab said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. The U.S.-based Lilly beat rival Novo Nordisk ( opens new tab in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May, according to data from research firm PharmaTrac. With its mass-market pricing, Mounjaro could become a mainstay in obesity and diabetes management in India, PharmaTrac said. The global demand for Lilly's Mounjaro and Novo's version Wegovy has skyrocketed in the last few years, even leading to shortages in a few countries, including the U.S. "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said on Thursday. Obesity and diabetes rates have been steadily climbing in India. A government survey conducted between 2019 and 2021 showed 24% of women and nearly 23% of men aged 15 to 49 were overweight or obese, up from 20.6% and 19%, respectively, in 2015-2016. In addition, the number of adults with diabetes is projected to increase to more than 124 million by 2045 from 74.2 million in 2021, according to the International Diabetes Federation. Indian drugmakers are now racing to develop cheaper versions of the weight-loss drugs to grab a share of the market estimated to be around $150 billion by the early 2030s. Semaglutide, the active ingredient in Wegovy, is likely to go off-patent in 2026 in India. ($1 = 86.6125 Indian rupees)
Telegraph
5 hours ago
- Telegraph
Cancer patients warned not to use weight-loss jabs
Cancer patients should not take 'quick fix' weight-loss jabs unless under specialist care, experts have warned. Macmillan Cancer Support said there had been a surge in people asking about the drugs, such as Wegovy and Mounjaro, but that there was not enough evidence about how they might affect cancer treatment. It said there was already evidence the injections may affect how other medicines are absorbed by the body, and that this could include cancer drugs. The manufacturers acknowledge the weight-loss jabs may affect the absorption of other drugs. The contraceptive pill and hormone replacement therapy (HRT) are among treatments experts have said are affected when taken orally. It is thought the mechanism by which the drugs make a person feel fuller and reduce their appetite – called delayed gastric emptying – also slows down the rate at which medicines are absorbed by the gut. Dr Owen Carter, national clinical adviser at Macmillan Cancer Support, said there had been 'a noticeable increase in calls to Macmillan's free support line and a flurry of messages on our peer-to-peer online community about weight-loss drugs'. 'We know that cancer affects everybody differently and it's understandable that lots of people are interested in new drugs which accelerate weight loss, particularly if they want to manage their weight before or after treatment for cancer,' he said. 'While 'quick fixes' may seem attractive, we simply do not know enough about the long-term impact of these weight-loss medications to recommend them if they're not prescribed by a specialist.' He also said that 'certain weight-loss medications carry warnings about a potential link with thyroid cancer'. He added that 'eating well and staying as active as possible are proven to help people feel better, increase their energy levels and strengthen their immune systems, which can help them to manage their weight and cope better with cancer treatment'. Weight-loss drugs have been available on the NHS to a select few patients via specialist weight management clinics. The majority of the estimated 1.5 million people taking the drugs in the UK are accessing them privately for around £200 a month, often from online pharmacies. Later this month, GPs will be able to prescribe one of the drugs, Mounjaro, to obese patients. Last week, Prof Sir Stephen Powis, the NHS England national medical director, said they could be as transformative as statins.
